Ipragliflozin, a sodium–glucose cotransporter 2 inhibitor, reduces bodyweight and fat mass, but not muscle mass, in Japanese type 2 diabetes patients treated with insulin: A randomized clinical trial

Abstract Aims/Introduction Sodium–glucose cotransporter 2 inhibitors reduce bodyweight (BW) by creating a negative energy balance. Previous reports have suggested that this BW reduction is mainly loss of body fat and that ~20% of the reduction is lean mass. However, the effects of sodium–glucose cot...

Descripció completa

Dades bibliogràfiques

Autors principals:	Hideka Inoue, Katsutaro Morino, Satoshi Ugi, Sachiko Tanaka‐Mizuno, Keiko Fuse, Itsuko Miyazawa, Keiko Kondo, Daisuke Sato, Natsuko Ohashi, Shogo Ida, Osamu Sekine, Masahiro Yoshimura, Kiyoshi Murata, Katsuyuki Miura, Hisatomi Arima, Hiroshi Maegawa, the SUMS‐ADDIT‐1 Research group
Format:	Artigo
Idioma:	Inglês
Publicat:	Wiley 2019-07-01
Col·lecció:	Journal of Diabetes Investigation
Matèries:	Bodyweight Sodium–glucose cotransporter 2 inhibitor Treatment drug
Accés en línia:	https://doi.org/10.1111/jdi.12985
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!